君实生物(01877.HK) 公布,公司产品特瑞普利单抗注射液(商品名:拓益)新增4项适应症成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》乙类范围,新版国家医保目录将于2025年1月1日起正式实施。至今,拓益内地获批的10项适应症已全部纳入国家医保目录。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-28 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.